MCL is a rare and aggressive blood cancer that usually occurs in older adults. VELCADE, in combination with other agents, is currently licensed to treat patients with Multiple
TAS-102 achieved statistically significant improvements in overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC) whose disease had progressed after or who
In the long history of diabetes treatment, both Sanofi and Takeda have brought to market numerous therapeutic drugs to treat diabetes over the years and have built up
These two patents broadly cover methods and uses for AC-201 as monotherapy or in combination with other lipid lower agents to treat patients with type II diabetes and
Following the launch of Herceptin SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche’s oncology products using Halozyme’s patented EnhanzeTM (recombinant
The company’s Vice President of Sales Callum Baylis-Duffield said of the exemption, "As we gear up to commence marketing Phytofare in the coming quarter, qualifying for this exemption
The patent claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer. Prostate cancer typically
"DTCC" stands for "The Depository Trust Clearing Corporation." DTCC is a member of the U.S. Federal Reserve System. It is a limited trust company under New York State
Tumor types were selected based on clinical observations in the phase 1 study and a detailed analysis of potential patient stratification biomarkers across tumor indications. The study will
Roclatan achieved its primary efficacy endpoint of statistically significant superiority over each of its components on day 29. The Phase 2b 28-day clinical trial included 297 patients. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.